These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15811593)

  • 21. Community dysfunction in schizophrenia: rate-limiting factors.
    Bozikas VP; Kosmidis MH; Kafantari A; Gamvrula K; Vasiliadou E; Petrikis P; Fokas K; Karavatos A
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):463-70. PubMed ID: 16442195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia.
    Levine J; Stahl Z; Sela BA; Ruderman V; Shumaico O; Babushkin I; Osher Y; Bersudsky Y; Belmaker RH
    Biol Psychiatry; 2006 Aug; 60(3):265-9. PubMed ID: 16412989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
    Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
    J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ondansetron reduces the craving of biologically predisposed alcoholics.
    Johnson BA; Roache JD; Ait-Daoud N; Zanca NA; Velazquez M
    Psychopharmacology (Berl); 2002 Apr; 160(4):408-13. PubMed ID: 11919668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative study of neurocognitive function in euthymic bipolar patients and stabilized schizophrenic patients.
    Sánchez-Morla EM; Barabash A; Martínez-Vizcaíno V; Tabarés-Seisdedos R; Balanzá-Martínez V; Cabranes-Díaz JA; Baca-Baldomero E; Gómez JL
    Psychiatry Res; 2009 Oct; 169(3):220-8. PubMed ID: 19758705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galantamine improves cognition in schizophrenic patients stabilized on risperidone.
    Schubert MH; Young KA; Hicks PB
    Biol Psychiatry; 2006 Sep; 60(6):530-3. PubMed ID: 16806095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased visceral sensitivity in Giardia-induced postinfectious irritable bowel syndrome and functional dyspepsia. Effect of the 5HT3-antagonist ondansetron.
    Dizdar V; Gilja OH; Hausken T
    Neurogastroenterol Motil; 2007 Dec; 19(12):977-82. PubMed ID: 17973637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spatial working memory and problem solving in schizophrenia: the effect of symptom stabilization with atypical antipsychotic medication.
    Snyder PJ; Jackson CE; Piskulic D; Olver J; Norman T; Maruff P
    Psychiatry Res; 2008 Sep; 160(3):316-26. PubMed ID: 18579217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and neuropsychological correlates of insight in schizophrenia and bipolar I disorder: does diagnosis matter?
    Varga M; Magnusson A; Flekkøy K; David AS; Opjordsmoen S
    Compr Psychiatry; 2007; 48(6):583-91. PubMed ID: 17954145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of two prednisone exposures on mood and declarative memory.
    Brown ES; Beard L; Frol AB; Rush AJ
    Neurobiol Learn Mem; 2006 Jul; 86(1):28-34. PubMed ID: 16458545
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial.
    Chaudhry IB; Husain N; Husain MO; Hallak J; Drake R; Kazmi A; Rahman Ru; Hamirani MM; Kiran T; Mehmood N; Stirling J; Dunn G; Deakin B
    Trials; 2013 Apr; 14():101. PubMed ID: 23782463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sloreta.
    Sumiyoshi T; Higuchi Y; Itoh T; Matsui M; Arai H; Suzuki M; Kurachi M; Sumiyoshi C; Kawasaki Y
    Psychiatry Res; 2009 Jun; 172(3):180-3. PubMed ID: 19386475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial.
    Berk M; Copolov D; Dean O; Lu K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Judd F; Katz F; Katz P; Ording-Jespersen S; Little J; Conus P; Cuenod M; Do KQ; Bush AI
    Biol Psychiatry; 2008 Sep; 64(5):361-8. PubMed ID: 18436195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ondansetron amelioration of scopolamine induced cognitive deficits in three-panel runway apparatus in rats.
    Kumar N; Kela AK
    Indian J Exp Biol; 2004 Sep; 42(9):919-21. PubMed ID: 15462187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ondansetron - a promising adjunctive treatment for persistent schizophrenia.
    Kulkarni J; Thomas N; Hudaib AR; Gavrilidis E; Gurvich C
    J Psychopharmacol; 2018 Nov; 32(11):1204-1211. PubMed ID: 30359166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of ondansetron, a 5-HT3 receptor antagonist, in chronic fatigue syndrome: a randomized controlled trial.
    The GK; Bleijenberg G; Buitelaar JK; van der Meer JW
    J Clin Psychiatry; 2010 May; 71(5):528-33. PubMed ID: 20122367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals.
    Johnson BA; Ait-Daoud N; Ma JZ; Wang Y
    Alcohol Clin Exp Res; 2003 Nov; 27(11):1773-9. PubMed ID: 14634493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis.
    Monaca-Charley C; Stojkovic T; Duhamel A; De Seze J; Ferriby D; Vermersch P
    J Neurol; 2003 Oct; 250(10):1190-4. PubMed ID: 14586600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.